about
Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa BMagnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation.Transient upregulation of PGC-1alpha diminishes cardiac ischemia tolerance via upregulation of ANT1.Caloric restriction in leptin deficiency does not correct myocardial steatosis: failure to normalize PPAR{alpha}/PGC1{alpha} and thermogenic glycerolipid/fatty acid cycling.Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis.Protein kinase C-zeta phosphorylates insulin receptor substrate-1, -3, and -4 but not -2: isoform specific determinants of specificity in insulin signaling.SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via regulation of 14-3-3 zeta and BAD in H9c2 cellsGRP78 and CHOP modulate macrophage apoptosis and the development of bleomycin-induced pulmonary fibrosis.Deficiency of TDAG51 protects against atherosclerosis by modulating apoptosis, cholesterol efflux, and peroxiredoxin-1 expression.Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2).Molecular characterization of the first avian LDL receptor: role in sterol metabolism of ovarian follicular cells.Induction of the unfolded protein response after monocyte to macrophage differentiation augments cell survival in early atherosclerotic lesions.Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesionsVery low-density lipoprotein stimulates the expression of monocyte chemoattractant protein-1 in mesangial cellsUptake and metabolism of lipoprotein-X in mesangial cellsRole of lipoprotein-X in foam cell formation and rat mesangial cell proliferation
P50
Q28567690-F771EB18-C3A2-47C1-88BA-4F393979C82BQ32049423-DD8C9C2B-983F-41F2-BC79-8839E8C51A7DQ34101286-7DB45291-42DF-4015-B1DC-23261D239F05Q35062530-12454E7D-5BB7-43FB-977E-8B4C506F4E4CQ36477235-CAD2BDF7-A506-41C7-BC24-1DBE55FB1ABCQ36578889-BE206525-289C-4B7F-AFFF-35CB51DFD8D1Q36935639-86113A08-5FCE-4E20-A66E-08E7F19DE8FFQ39804171-77AAD627-D6F6-4CBD-8811-10E1B407FBEAQ43109046-64D371D3-0BC2-45FE-9646-5B119CE4507BQ44040646-D44D706B-5BB6-40F8-997C-6927BEE22F22Q44460218-BAFBAC73-19D7-4B60-981E-F6769AEFFFDEQ53294172-D0A8F406-B61A-4F41-8908-1E9AA17E5441Q61456219-6F4231E4-9DAC-4A39-97A1-2ED988D1C4A6Q73664710-51AD5D5C-D3DE-4583-9082-0DE34B742CDBQ73830132-C9A447F3-4392-43A4-A1D6-A0C0E91B8BB4Q73959134-A7D3BC39-1587-4F96-9671-A6D0D67D2B71
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Edward G Lynn
@ast
Edward G Lynn
@en
Edward G Lynn
@es
Edward G Lynn
@nl
type
label
Edward G Lynn
@ast
Edward G Lynn
@en
Edward G Lynn
@es
Edward G Lynn
@nl
prefLabel
Edward G Lynn
@ast
Edward G Lynn
@en
Edward G Lynn
@es
Edward G Lynn
@nl
P106
P21
P31
P496
0000-0002-8011-5558